News Updates

Alps Pharmaceuticals restrained by Delhi High Court from using the trademark Colispas

Gaurav Pathak
6 Nov 2014 11:25 AM GMT
Alps Pharmaceuticals restrained by Delhi High Court from using the trademark Colispas
Your free access to Live Law has expired
To read the article, get a premium account.
    Your Subscription Supports Independent Journalism
Subscription starts from
(For 6 Months)
Premium account gives you:
  • Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.
  • Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.
Already a subscriber?

Alps Pharmaceuticals reportedly has been restrained by Delhi High Court from “manufacturing, selling, trading and marketing medicinal and pharmaceutical products under the trademark Colispas or any other identical or similar mark”.

The High Court delivered the ruling on Wednesday while hearing a matter filed by Besto chem Formulations Ltd. As per reports, an inerim order was also passed in the matter in 2009 and it had stated, “the likelihood of confusion is not only real but could possibly result in adverse reactions to those using the product, believing the defendants’ (Alps Pharmaceuticals) products to be that of the plaintiff’s”.

Colispas is a drug that contains Dicycloverine Hyrochoride and is used to treat intestinal hypermotility, the symptoms of Irritable Bowel Syndrome (IBS) (also known as spastic colon). It relieves muscle spasms and cramping in the gastrointestinal tract by blocking the activity of acetylcholine on cholinergic (or muscarinic) receptors on the surface of muscle cells. It is a smooth muscle relaxant.

The drug that is manufactured by Alps Pharmaceuticals contains dicyclomine hydrochloride and paracetamol.

More news about trademark cases can be read here:

Delhi High Court bars infringement of ‘’ Trademark

Delhi High Court Restrains Nutralite’s look-alike from Infringing its Trademark

Soft Drink Giant PepsiCo wins Trademark battle over its Mineral Water brand.

Next Story